Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling

Major roadblocks to developing effective progesterone receptor (PR)-targeted therapies in breast cancer include the lack of highly-specific PR modulators, a poor understanding of the pro- or anti-tumorigenic networks for PR isoforms and ligands, and an incomplete understanding of the cross talk betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Singhal, Hari, Greene, Marianne E., Zarnke, Allison L., Laine, Muriel, Al Abosy, Rose, Chang, Ya-Fang, Dembo, Anna G., Schoenfelt, Kelly, Vadhi, Raga, Qiu, Xintao, Rao, Prakash, Santhamma, Bindu, Nair, Hareesh B., Nickisch, Klaus J., Long, Henry W., Becker, Lev, Brown, Myles, Greene, Geoffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796974/
https://www.ncbi.nlm.nih.gov/pubmed/29435103
http://dx.doi.org/10.18632/oncotarget.21378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796974/
https://www.ncbi.nlm.nih.gov/pubmed/29435103
http://dx.doi.org/10.18632/oncotarget.21378

Ejemplares similares